| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CompARE | 17-14 | intermediate and high-risk oropharyngeal |
To examine the outcomes of alternative treatments aiming to improve overall survival time in intermediate and high-risk oropharyngeal cancer and to compare Quality of Life (QoL), toxicity outcomes and swallowing function of these alternative treatments |
DSSG Group: Head & Neck
PRESERVE
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| PRESERVE | 20-04 | Resected oral cavity squamous cell carcinoma |
The purpose of this study is to compare oncologic outcomes, functional outcomes, and quality of life (QoL) in patients treated with standard radiotherapy volumes vs. radiotherapy to the primary site and pathologically involved hemi-neck only, omitting radiation to the pN0 hemi-neck(s). |
MK-3475-630/KEYNOTE-630
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK-3475-630/KEYNOTE-630 | CTRIAL-IE 20-08 | Melanoma |
This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS). |